- Home
- CAPL vs NTLA Comparison
CAPL vs NTLA Comparison
Compare CAPL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPL
- NTLA
- Stock Information
- Founded
- CAPL 1992
- NTLA 2014
- Country
- CAPL United States
- NTLA United States
- Employees
- CAPL N/A
- NTLA N/A
- Industry
- CAPL Oil Refining/Marketing
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CAPL Energy
- NTLA Health Care
- Exchange
- CAPL Nasdaq
- NTLA Nasdaq
- Market Cap
- CAPL 796.2M
- NTLA 794.5M
- IPO Year
- CAPL 2012
- NTLA 2016
- Fundamental
- Price
- CAPL $20.74
- NTLA $11.54
- Analyst Decision
- CAPL
- NTLA Buy
- Analyst Count
- CAPL 0
- NTLA 19
- Target Price
- CAPL N/A
- NTLA $35.11
- AVG Volume (30 Days)
- CAPL 26.5K
- NTLA 4.7M
- Earning Date
- CAPL 08-06-2025
- NTLA 08-07-2025
- Dividend Yield
- CAPL 10.14%
- NTLA N/A
- EPS Growth
- CAPL 30.34
- NTLA N/A
- EPS
- CAPL 0.80
- NTLA N/A
- Revenue
- CAPL $3,694,780,000.00
- NTLA $45,569,000.00
- Revenue This Year
- CAPL N/A
- NTLA N/A
- Revenue Next Year
- CAPL N/A
- NTLA N/A
- P/E Ratio
- CAPL $25.99
- NTLA N/A
- Revenue Growth
- CAPL N/A
- NTLA N/A
- 52 Week Low
- CAPL $18.43
- NTLA $5.90
- 52 Week High
- CAPL $25.73
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- CAPL 36.62
- NTLA 65.96
- Support Level
- CAPL $20.55
- NTLA $10.19
- Resistance Level
- CAPL $21.03
- NTLA $12.34
- Average True Range (ATR)
- CAPL 0.43
- NTLA 0.69
- MACD
- CAPL 0.02
- NTLA 0.22
- Stochastic Oscillator
- CAPL 16.90
- NTLA 76.77
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.